Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marina Biotech, a RNAi-based drug discovery and development company, presented and described their integrated technology platform for the discovery of multiple oligonucleotide-based drugs.
Subscribe to our email newsletter
Thestherapeutics include RNAi-, microRNA- and antisense-based drugs.
Marina Biotech recently entered into a partnership with Debiopharm to fully fund the development of its bladder cancer program using its proprietary DiLA2 delivery technology for local administration.
Marina also has a licensing partner in ProNAi which is funding a Phase 1 clinical trial using Marina’s proprietary Smarticles delivery technology for systemic administration.
Consequently, the company is now focusing its financial resources on the Phase 1b/2a clinical trial of CEQ508, the first drug candidate in a novel class of therapeutic agents utilizing the transkingdom RNA interference (tkRNAi) platform, in Familial Adenomatous Polyposis (FAP), and the development of its Conformationally Restricted Nucleotide technology (CRN) for the development of single-stranded oligonucleotide therapies.
Marina Biotech president and CEO Michael French said the company plans to focus its research efforts in expanding opportunities in systemic administration by applying its CRN technology to the development of single-stranded oligonucleotide therapeutics.